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Cell-type speciﬁc regulation of gene expression requires the activation of promoters by distal
genomic elements deﬁned as enhancers. The identiﬁcation and the characterization of
enhancers are challenging in mammals due to their genome complexity. Here we develop
CapStarr-Seq, a novel high-throughput strategy to quantitatively assess enhancer activity in
mammals. This approach couples capture of regions of interest to previously developed Starr-
seq technique. Extensive assessment of CapStarr-seq demonstrates accurate quantiﬁcation
of enhancer activity. Furthermore, we ﬁnd that enhancer strength is associated with binding
complexity of tissue-speciﬁc transcription factors and super-enhancers, while additive
enhancer activity isolates key genes involved in cell identity and function. The CapStarr-Seq
thus provides a fast and cost-effective approach to assess the activity of potential enhancers
for a given cell type and will be helpful in decrypting transcription regulation mechanisms.
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R
ecent advances in epigenomics have enabled genome-wide
identiﬁcation of enhancers in various tissues and species1.
However, these do not allow direct quantiﬁcation of
enhancer activity. Besides, previous studies have focused their
efforts on the isolation of enhancers using high-throughput gene
reporter assays coupled to cell sorting2,3 or tags sequencing4,
providing limited quantitative information. Recently, a technique
named Starr-seq enabling genome-wide quantiﬁcation of enhan-
cer activity in Drosophila cell lines has been developed5–7.
Although Starr-seq was also applied to human cells using selected
BACs5, one major limitation for its implementation to mammalian
systems resides in their genome size and complexity, rendering
challenging the preparation of representative libraries and
requiring very high sequencing depth. To circumvent this
problem, we have developed CapStarr-seq, a technique capturing
genomic sequences of interest for high-throughput assessment of
enhancer activity in mammals. We demonstrate the accuracy of
the approach to quantify enhancer activity and its efﬁciency to
identify known enhancers in a murine T-cell model. Furthermore,
we show that enhancer activity assessed by CapStarr-seq is linked
to the epigenetic environment, the transcription factors complexity
and the genomic conservation. Finally, we illustrate the interest
of CapStarr-seq to study gene regulation of complex loci.
CapStarr-Seq is applicable to a wide range of biological
questions and will provide an efﬁcient tool to better decipher
mechanisms involved in gene regulation.
Results
Experimental design of the CapStarr-seq approach. To deﬁne
cis-regulatory modules (CRMs) in developing mouse thymocytes,
we analysed DNaseI-seq along with ChIP-seq for ETS1, GATA3,
HEB (TCF12), Ikaros, RUNX1 and TCF1 lymphoid-speciﬁc
transcription factors (TFs) obtained from puriﬁed CD4þCD8þ
(double positives, DP) thymic population, using a combination of
published and newly generated data (see Methods section and
Supplementary Tables 1 and 2). We identiﬁed a set of 7,542
putative CRMs based on the overlap between DNaseI hypersen-
sitive sites (DHS) and regions bound by at least one of the six TFs
(average size of the CRMs was 188 bp). To test the enhancer
activity of these CRMs we developed CapStarr-seq, a novel
approach coupling capture of deﬁned regions to the previously
developed Starr-seq technique5 (Fig. 1a; see also Methods
section). As a negative control, we included 69 DHS bound by
the insulator factor CTCF, which represent open chromatin
regions not expected to display enhancer function. In brief, DNA
fragments of B400 bp were captured on a custom-designed
microarray covering the complete list of CRMs and cloned by
homologous recombination into the mammalian Starr-seq
vector5. The CapStarr-seq library was transfected into the
mouse T-cell line P5424 or the ﬁbroblast cell line 3T3, used as
a non-lymphoid control. The P5424 cell line is originated from
early developing T cells and resembles DP thymocytes at
phenotypic and transcriptomic levels (ref. 8 and Supplementary
Fig. 1a,b). Analyses of GFP expression by FACS demonstrated
global enhancer activity of inserted CRMs (Supplementary
Fig. 1c). Finally, targeted RNA-seq was performed on an Ion
PGM sequencer allowing rapid assessment of enhancer activity.
As controls, we sequenced the cloned CRM libraries obtained
before (hereafter, input) and after transfection. We observed a
high recovery of captured CRMs in the input sample (median
coverage of 76 FPKM; Supplementary Fig. 1d) and no bias due to
transfection (Supplementary Fig. 1e). Moreover, the two
CapStarr-seq replicates performed in P5424 cells were highly
correlated (R2¼ 0.90; Supplementary Fig. 1f), indicating high
reproducibility of the assay.
CapStarr-Seq accurately assesses enhancer activity. To deﬁne
the enhancer activity of each region, we calculated the fold change
(FC) of CapStarr-seq over the input signals for each CRM. We
then deﬁned three groups of CRMs based on their FC values:
inactive (FCo1.5), weak (1.5rFCo3) and strong (FCZ3)
(Fig. 1b and Supplementary Data 1). Strikingly, all the enhancers
known to be active in developing T cells displayed either weak or
strong CapStarr-seq activity in P5424, but not in 3T3 cells (Fig. 1b
and Supplementary Fig. 2). Notably, the Tcra (Ea) and Tcrb (Eb)
enhancers, representing the archetypes of strong T-cell enhan-
cers9, were found within the top active CRMs in P5424 cells
(Fig. 1b,c). In contrast, a CRM close to the ubiquitously expressed
Actb gene was active in both cell lines (Supplementary Fig. 2),
while 91% of DHS bound by the insulator factor CTCF were
found inactive by CapStarr-seq (Fig. 1b and Supplementary Data
2). Thus, the CapStarr-seq approach recapitulates the activity of
known T-cell enhancers.
To independently conﬁrm the accuracy of CapStarr-seq to
identify active enhancers and to discriminate between weak and
strong enhancer activity, we tested 45 CRMs in a classical
luciferase reporter assay (Fig. 1d and Supplementary Data 3). Of
37 CRMs called active by the CapStarr-seq, 31 displayed
signiﬁcant enhancer activity in the luciferase assay (Student
t-test; Po0.01; 12 out of 17 weak and 19 out of 20 strong CRMs).
On the contrary, only one of the eight inactive CRMs had
signiﬁcant enhancer activity. Furthermore, the set of strong
CRMs demonstrated a statistically higher enhancer activity in the
luciferase assay as compared with the weak CRMs (Welch t-test;
P¼ 0.0032). Thus, consistency between the two independent
reporter assays indicates that high-throughput assessment of
enhancer activity by CapStarr-seq is highly accurate and
quantitative.
CRM activity reﬂects epigenetic status of endogenous loci. To
explore whether CapStarr-Seq results reﬂect the epigenetic status
of endogenous enhancers, we analysed ChIP-seq data from the
P5424 cell line for H3K4me1, H3K4me2 and RNA-Polymerase II
(Pol II), three features generally correlated with enhancer
activity10. Strong CRMs displayed the highest level of Pol II and
H3K4 methylations, while weak CRMs displayed intermediate
levels, indicating a positive and quantitative relationship between
the CapStarr-seq signal and active epigenetic features
(Supplementary Fig. 3a). Similarly, the activity of CRMs deﬁned
in P5424 cells, but not the one deﬁned in 3T3 cells, was associated
with higher levels of Pol II, H3K4me1 and H3K27ac in primary
DP thymocytes (Fig. 2a). For H3K27ac, which is speciﬁcally
associated with active enhancers10, the differences between the
three CRM sets were highly signiﬁcant when comparing the
P5424 selection, but not the 3T3 selection. We and others have
previously shown that active enhancers are speciﬁcally enriched
in H3K4me3 (refs 11–13). As high levels of H3K4me3 are
generally found in the vicinity of transcription start sites (TSS)14,
we analysed H3K4me3 enrichments at CRMs distal from any TSS
(Supplementary Fig. 4b). We found that P5424-deﬁned active
CRMs were signiﬁcantly associated with higher levels of
H3K4me3 in both P5424 and DP cells, thus further supporting
the link between H3K4 trimethylation and active enhancers.
Besides, inactive CRMs were signiﬁcantly associated with higher
levels of the repressive epigenetic mark H3K9me3 and
nucleosome occupancy assessed by MNase-seq (Supplementary
Fig. 4a; note that no consistent differences were observed with
H3K27me3), suggesting that inactive CRMs are often in a more
closed chromatin conﬁguration and epigenetically silenced,
consistent with previous ﬁnding15. To correlate the activity of
the CRMs with gene expression we associated each CRM to the
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surrounding genes using the GREAT tool16. Although genes
might be skipped by enhancers17, we found that active enhancers
in P5424 cells were associated with genes expressed at
signiﬁcantly higher levels in both P5424 cells and DP
thymocytes (Supplementary Fig. 3b and Fig. 2b). Furthermore,
genes associated with strong enhancers displayed signiﬁcant up-
and downregulated expression centred at the DP stages (Fig. 2c).
Thus, CRM activity assessed by CapStarr-seq reﬂects epigenetic
and transcriptomic status of endogenous loci demonstrating that
this approach provides quantitative and qualitative information
about enhancer activity in mammals.
CRM activity is linked to TF occupancy and DNA conservation.
Having validated the CapStarr-seq approach, we asked whether
enhancer activity was linked to TF occupancy. First, we quantiﬁed
the ChIP-Seq signal around the three sets of CRMs for the six TFs
initially used to deﬁne the CRMs (Fig. 3a). Enhancer activity was
associated with the strength of ChIP-seq signal for ETS1, HEB,
Ikaros, RUNX1 and TCF1. Unexpectedly, the signal for GATA3
was found to be stronger in inactive CRMs as compared with
active CRMs, suggesting either a repressive or a pioneering role
for this factor. Motif discovery based on the CRM sets identiﬁed
only the motifs corresponding to the six TFs used in this study
(Supplementary Fig. 5a; note that ETS1 and Ikaros TFs share the
same binding motif18). Moreover, the discovery of GATA motif
only in inactive enhancers was consistent with the ChIP-seq
results for GATA3. We next asked whether enhancer activity was
associated with the complexity of the CRMs by scanning the
binding motifs identiﬁed for the six TFs by ChIP-seq
(Supplementary Fig. 5b; overlapping ETS1 and Ikaros sites were
count only once). The number of distinct binding sites per CRM
was signiﬁcantly higher in strong CRMs with respect to weak and
inactive CRMs (P¼ 4e 3 and P¼ 3e 4, respectively; Mann–
Whitney U-test; Supplementary Fig. 5c). Similarly, we observed
that enhancer activity was associated with the number of TFs
bound per CRM (Fig. 3b). Indeed, CRMs bound by only one TF
were preferentially inactive, while weak and strong CRMs were
signiﬁcantly associated with either 2–4 or 4–5 different TFs,
respectively. The reduced enrichment for simultaneous binding of
the six TFs in the case of strong CRMs is likely due to the fact that
GATA3 is poorly associated with active enhancers. The same
tendency was observed when analysing the patterns of enriched
CRM sets with respect to the number of distinct TFBS
(Supplementary Fig. 5d). A striking example is provided by the
Ets2 locus where only the CRM bound by ﬁve TFs (all except
GATA3) displays strong enhancer activity (Fig. 4a). Finally, we
addressed the question of whether CRM activity was linked
to sequence conservation. We computed the phylogenetic
conservation among mammalian species for the three sets of
CRMs. As shown in Supplementary Fig. 6, enhancer activity is
associated with signiﬁcantly increased conservation (Po1e 3;
Mann–Whitney U-test), suggesting that highly active enhancers
are under strong negative selection19. Thus, enhancer activity
appears associated with the binding complexity of tissue-speciﬁc
TFs and sequence conservation.
Super-enhancers are enriched in strong enhancers. Super-
enhancers were recently deﬁned as a class of cis-regulatory
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Figure 1 | Design and experimental validation of the CapStarr-seq approach. (a) CapStarr-seq experimental scheme (see Methods for details).
(b) CRMs were ranked in function of their CapStarr-seq fold change (FC) in P5424 cells. CRM activity was deﬁned as follows: inactive (FCo1.5),
weak (1.5rFCo3) and strong (FCZ3). Inactive, weak and strong CRMs are highlighted by green, orange and red background, respectively. Known and
characterized T-cell enhancers are plotted in red and were all identiﬁed as active CRMs. The CapStarr-seq proﬁles of these CRMs are shown in Figure 1c
and Supplementary Fig. 2. CTCF-bound CRMs are indicated in green. (c) CapStarr-seq proﬁles highlighting the Tcra (Ea; top panel) and Tcrb (Eb; bottom
panel) enhancers, which are two strong T-cell enhancers. Each track represents the normalized signal of the CapStarr-seq in the P5424 cell line
(two replicates are shown), the 3T3 cell line or the input (captured library). Classiﬁcation of the CRM activity is indicated by coloured rectangles (green:
inactive; orange: weak; red: strong). Mouse genomic coordinates and RefSeq genes are indicated in the top and bottom of each panel, respectively.
(d) Enhancer activity of 45 CRMs (8 inactive, 17 weak and 20 strong) was assessed by luciferase reporter assay in triplicate. Values are expressed as the
mean fold increase in luciferase counts over the pGL3-promoter vector and normalized by the Renilla intensities (detailed results are presented in the
Supplementary Table 3). Y-axis is in Log2 scale. The P values are indicated as follows: *Po0.05; **Po0.01; ***Po0.001 (Student’s t-test).
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elements spanning large genomic regions associated with clusters
of individual DHS and high levels of epigenetic marks, such as
H3K27ac20,21. Super-enhancers were proposed to be more
speciﬁcally enriched in active enhancers21. To address this issue
in a high-throughput manner, we deﬁned super-enhancers in DP
thymocytes based on H3K27ac signal, using ROSE tool as
previously described20,21. We found that the proportion of CRMs
overlapping H3K27ac peaks within super-enhancers increases in
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Figure 2 | CapStarr-seq reﬂects epigenetic status of endogenous enhancers. (a) Average proﬁles of H3K27ac, H3K4me1 and Pol II ChIP-seq in the
mouse DP thymocytes for CRMs identiﬁed by CapStarr-Seq as inactive, weak or strong in P5424 (left panels) or in 3T3 (right panels). Statistically
signiﬁcant differences (Po0.05) calculated on the regions highlighted in grey are indicated (Mann–Whitney U-test). (b) Boxplot showing the expression
distribution in primary thymocytes (DPbl: DP blasts) of genes associated with inactive, weak and strong CRMs deﬁned in P5424 cells. (c) Expression
dynamic during T-cell differentiation of genes associated with inactive, weak and strong CRMs deﬁned in P5424 cells. Cell populations are as deﬁned by the
Immunological Genome Project37 and are ordered from less to most differentiated stages. DPbl¼ double-positive blast; DPsm¼ double-positive small;
DN2-4¼ double-negative 2–4; ETP¼early thymic progenitors; ISP¼ immature single positive; 4SP and 8SP¼ single-positive cd4 and cd8, respectively.
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*Po0.05; **Po0.01; ***Po0.001 (Student’s t-test).
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function of CRM activity. Indeed, they represent 34, 38 and 48%
of the inactive, weak and strong CRMs, respectively (Fig. 4b).
Remarkably, CRMs overlapping H3K27ac peaks within super-
enhancers were signiﬁcantly and speciﬁcally enriched in strong
enhancers as compared with those overlapping H3K27ac peaks
outside super-enhancers (Fig. 4c). Hence, while super-enhancers
overlap many inactive CRMs (for example., Ets2 locus, Fig. 4a;
Ikzf1 and Runx1 loci, Supplementary Fig. 7), they have a higher
probability of containing strong enhancers.
Additive enhancer activity reveals cell identity genes. Tissue-
speciﬁc gene regulation is thought to be achieved by the combi-
natorial effect of multiple enhancers22. Hence, we asked whether
analysis of additive enhancer strength could provide functional
information concerning the regulated genes. We selected genes
associated with at least one active CRM and computed the sum of
CapStarr-seq FC of their active CRMs to obtain a global enhancer
activity for each of these loci (see Methods). Genes ranking in
function of the global enhancer activity reveals the existence of
375 loci displaying substantially higher global enhancer activity
(Fig. 4d and Supplementary Data 4). These highly active loci
(hereafter, HAL) were expressed at signiﬁcantly higher levels in
DP thymocytes as compared with other active loci (Fig. 4e) and
were exclusively involved in T-cell-related functions (Fig. 4f).
Note that the set of ‘other active loci’ was not signiﬁcantly
enriched in any biological process. Remarkably, the set of HAL
included most of the known regulators of T-cell differentiation
and function (Fig. 4d), namely Bcl11b, Runx1, Ets1, Ikzf1, Lef1,
Myb and Tcf7, which encode crucial TFs involved in early T-cell
differentiation23. Moreover, HAL were often associated with
several weak and strong CRMs (for example, Ets2 locus, Fig. 4a;
Ikzf1 and Runx1 loci, Supplementary Fig. 7). This suggests that
key genes involved in cell identity are regulated by additive
enhancer activities, likely allowing integration of different
environmental inputs and conferring higher transcriptional
output.
Discussion
We developed a CapStarr-seq approach coupling capture of
deﬁned genomic regions to the previously developed Starr-seq
technique. Our method takes advantage of targeted enrichment of
CRMs of interest as well as rapid sequencing with an Ion PGM
technology, providing a fast and cost-effective approach for the
study of enhancer activity in mammals. As an initial assessment
of the CapStarr-seq technique, we analysed here a set of 7,542
CRMs overlapping DHS bound by at least one lymphoid TF in
primary developing mouse thymocytes. We extensively validated
the accuracy of CapStarr-seq to quantify enhancer activity in
mammals and demonstrated its robustness to discriminate
between weak and strong enhancers. We explored the beneﬁts
of this approach on the understanding of molecular basis driving
enhancer activity, including epigenetic features and combinatorial
binding of TFs. Moreover, we showed that computing additive
enhancer activity enables the identiﬁcation of HAL that overlap
genes highly relevant to cell identity.
Starr-seq has been efﬁciently achieved with the full drosophila
genome5, which representB48-fold the set of CRMs analysed in
this study and B7-fold the estimated genome space covered
by all potential enhancers in a given mammalian cell type
(estimation based on the average number of total DHS per cell
type24). It is therefore possible to extend the use of CapStarr-seq
to a larger genomic scale, providing that the genomic regions
could be captured. This might be achieved by either using higher-
density arrays and/or combining multiple arrays. In the future, it
is expected that the CapStarr-Seq approach will be applied to
explore the activity of all potential enhancers for a given cell type,
while including additional negative controls like random or
DNaseI-insensitive regions.
Together our ﬁndings illustrate how the CapStarr-seq techni-
que will further help to the functional assessment of mammalian
enhancers that are active in different cellular systems. This
approach will be also useful for thorough characterization of
enhancer subsets involved in speciﬁc pathways or induced by
speciﬁc stimuli.
Methods
Mouse and cell culture. C57/Bl6 mice were housed under speciﬁc pathogen-free
conditions and handled in accordance with French and European directives
(EU Agreement N A-13013 03). This work was approved by the Aix-Marseille
University Institutional Animal Care and Use Committee. Only male mice were
used in this study and were killed for analysis between 4 and 6 weeks of age. DP
thymocytes were puriﬁed as previously described25. P5424 cells8 (kindly provided
by Dr. Eugene Oltz, Washington, USA) and NIH-3T3 (3T3, ATCC: CRL-1658)
cells were cultured in RPMI medium (Life technologies) supplemented with 10%
heat-inactivated FBS (PAA) at 37 C.
ChIP-seq. Chromatin preparation and ChIPs25 were performed with DP
thymocytes and P5424 cell line. In brief, after puriﬁcation, crosslinked nuclei from
DP thymocytes or P5424 cells were sonicated using a Misonix 4000 (Misonix Inc)
sonicator for 7 cycles (30 s on, 30 s off, amplitude 40). After the addition of Triton
X-100 to a ﬁnal concentration of 1%, debris was removed through centrifugation at
20,000 g and 4 C for 20min. Extracts were incubated overnight at 4 C on a
rotating wheel with antibodies bound to protein G Dynabeads (Life technologies).
The anti-TCF1 antibodies used were # 2203 (cell signaling, 20mL); the anti-HEB
antibodies used were # sc-357X (Santa cruz, 10 mg); the anti-RNA Polymerase II
used were # sc-899x (Santa cruz, 4 mg); the anti-H3K4me1 antibodies used were #
ab8895 (Abcam, 1 mg); the anti-H3K4me2 used were # ab32356 (Abcam, 1 mg); the
anti-H3K4me3 used were # ab8580 (Abcam, 1 mg); the anti-H3K9me3 used were #
ab8898 (Abcam, 2 mg) and the anti-H3K27ac used were # ab4729 (Abcam, 2 mg).
Beads were washed ﬁve times in RIPA buffer (50mM Hepes pH 7.6, 500mM LiCl,
1mM EDTA pH 8, 1% NP-40, 0.7% Na-Deoxycholate), once in TEþ (10mM Tris
pH 8, 1mM EDTA pH 8, 50mM NaCl) and once in TE (10mM Tris pH 8, 1mM
EDTA pH 8). Immunoprecipitated chromatin was recovered from the beads with
two subsequent elution steps at 65 C for 15 and 10min in elution buffer (NaHCO3
100mM, 1% SDS). The two eluates were combined and incubated at 65 C
overnight (13–15 h) for crosslink reversal in the presence of proteinase K. DNA
was puriﬁed using QIAquick PCR puriﬁcation kit (Qiagen). At least 1 ng of ChIP
was used for library preparation. Libraries for the TCF1 and HEB ChIPs in
DP thymocytes were prepared according to the SOLiD ChIP-Seq protocol
and sequenced on 5500 SOLiD System (Life technologies), according to the
manufacturer’s instructions. Libraries for ChIPs against H3K4me1, H3K4me2,
H3K4me3, H3K9me3, H3K27ac and Pol II were prepared according to Illumina
ChIP-Seq protocol and sequenced on a HighSeq 2000 (Illumina) according to the
manufacturer’s instructions.
DNaseI-seq. DNase I digestion26 and high-throughput sequencing were
performed on intact nuclei from DP thymocytes. In brief, nuclei were extracted
using NP-40 in an isotonic buffer. The NP-40 detergent was removed and the
nuclei were incubated for 3min at 37 C with limiting concentrations of the DNA
endonuclease, DNase I (Sigma-Aldrich) supplemented with Ca2þ and Mg2þ . The
digestion was stopped with EDTA and the samples were treated with proteinase K.
The small double-hit fragments (o500 bp) were recovered by high-resolution
agarose gel electrophoresis followed by gel puriﬁcation. DNase I hypersensitive
sites were sequenced on a 5500 SOLiD System.
ChIP-seq and DNaseI-seq data processing. ChIP-seq data sets for Pol II, MNase,
the transcription factors (TFs) ETS1, GATA3, Ikaros, RUNX1 and CTCF in DP
thymocytes were downloaded from Gene Expression Omnibus (GEO) database
(Supplementary Table 2). ChIP-seq for all TFs and DNaseI-seq samples were
mapped to the mouse genome (assembly NCBI37/mm9) using BFast tool (v0.7.0)27
and only reads that have a unique best scoring alignment were used. ChIP-seq for
Pol II, H3K4me1, H3K4me2 and H3K4me3 in P5424 cell line was mapped to the
mouse genome (assembly NCBI37/mm9) using the Illumina’s integrated Eland
software. To exclude redundancies from PCR ampliﬁcation, we counted only
unique fragments. Fragment size was computed using the Hypergeometric
Optimization of Motif EnRichment (HOMER) tool (v6.1)28 (Supplementary
Table 1). Read-count intensity proﬁles (wiggle ﬁles) were constructed by elongating
each mapped read to the estimated fragment size, and counting the elongated read
overlaps within a window of 50 nucleotides after normalization of the proﬁle by the
number of mapped reads. Peak-calling was performed using the HOMER tool with
default settings (FDR: 0.001; local and input fold enrichment: 4.0).. Processed data
for Pol II, MNase and epigenetic modiﬁcations H3K4me1, H3K4me3, H3K27ac
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and H3K27me3 in DP thymocytes were downloaded from GEO25,29,30. ChIP-seq
data were visualized using the Integrated Genome Browser (http://bioviz.org/igb/).
Identiﬁcation of CRMs. CRMs were extracted by merging peaks of TFs ETS1,
GATA3, HEB, Ikaros, RUNX1 and TCF1 that overlap DNaseI peaks. These
resulted in a set of 7,542 CRMs that were retained to design the capture microarray
(Supplementary Data 1; the average size of the CRMs was 188 bp). As a control, we
included 69 CTCF peaks (Supplementary Data 2).
Generation of genomic library for CapStarr-seq. Genomic DNA from C57bl6
mouse thymus was sheared by sonication (Diagenode pico), and DNA fragments
between 330 and 430 bp were size-selected on a 1.2% high-resolution agarose gel
(Sigma-Aldrich) and puriﬁed using Qiaquick gel extraction kit (Qiagen). Size-
selected genomic DNA was analysed by Bioanalyzer (Agilent) and the average size
estimated at 400 bp. Ion Torrent adapters were ligated to 8 mg of size-selected DNA
fragments using Ion Plus Fragment Library Kit (Life Technologies) following the
manufacturer’s instructions except for the ﬁnal PCR ampliﬁcation. Forty individual
PCR reactions (98 C for 2min; followed by 10 cycles of 98 C for 20 s, 65 C for
15 s, 72 C for 15 s) with 2 ml of adaptor ligated DNA were performed using KAPA
Hiﬁ Hot Start Ready Mix (KAPA Biosystems) and primers (fw: 50-TAGAGCAT
GCACCGGAACCATCTCATCCCTG*C*G*T*G-30 and rw: 50-GGCCGAATTCG
TCGAAACCACTACGCCTCCGC*T*T*T*C-30 ; * indicates phosphorothioate
bonds) that add a speciﬁc 15 nucleotides extension for directional cloning by
homologous recombination (In Fusion HD, Clontech). PCR reactions were pooled
and puriﬁed with Agencourt AMPureXP DNA beads (Ratio beads/PCR 1.2;
Beckman Coulter).
Capture of genomic library. For target enrichment, a home-designed 3 bp
resolution oligonucleotide microarray covering the 7,542 CRMs deﬁned in section
5 was constructed using the SureSelect technology (Agilent) and the eArray tool
default setting (https://earray.chem.agilent.com/earray/). The genomic library was
hybridized on the microarray as outlined in the Agilent SureSelect DNA Capture
Array protocol (Agilent). In brief, 10 mg of PCR (in 138 ml), 5 ml Blocking oligo 1
50-(TAGAGCATGCACCGGAACCATCTCATCCCTG*C*G*T*G)-30 (200 mM),
5 ml Blocking oligo 2 50-(GGCCGAATTCGTCGAAACCACTACGCCTCCGC*T
*T*T*C)-30 (200 mM), 5 ml Blocking oligo 3 50-(CACGCAGGGATGAGATGGTT
CCGGTGCATGC*T*C*T*A)-30 (200 mM), 5 ml Blocking oligo 4 50-(GAAAGCG
GAGGCGTAGTGGTTTCGACGAATTC*G*G*C*C)-30 (200 mM), 50ml Mouse
Cot-1 DNA (1mgml 1), 52ml 10 blocking buffer and 260 ml 2 Hyb buffer
were mixed and denatured at 95 C for 3min followed by transfer to 37 C for
30min. The mixture was centrifugated at 17,800 g for 1min. Four hundred and
ninety microlitres of hybridization mixture was dispensed onto the centre of a
gasket slide in the hybridization chamber. The oligonucleotide array was placed
with the active side contacting the hybridization mixture. The resulting slide-gasket
sandwich was incubated at 65 C for 65 h on a rotisserie in an Agilent hybridization
oven. The aCGH Wash buffer 2 was preheated at 37 C in a hybridization oven
overnight before washing. Following hybridization, the slide-gasket sandwich was
disassembled in aCGH wash buffer 1 at room temperature. The slide was washed
for 10min in wash buffer 1 and transferred to wash buffer 2 at 37 C and washed
for 5min. Slides were dried and 490 ml of nuclease-free water were added to a new
gasket slide and the dried marray was placed atop as described earlier, creating a
fresh slide-gasket sandwich. The slide-gasket sandwich was incubated at 95 C for
10min on a rotisserie in an Agilent hybridization oven. After heat denaturation,
the eluate was recovered with a 1-ml 30G syringe. The eluted DNA was puriﬁed
with Agencourt AMPureXP DNA beads (Ratio beads/PCR 1.8) and eluted in 80 ml.
Twenty independent 25ml PCR (98 C for 2min; followed by 20 cycles of 98 C for
20 s, 65 C for 15 s, 72 C for 15 s) reactions with 4 ml of captured DNA were
performed using KAPA Hiﬁ Hot Start Ready Mix and primers (fw: 50-TAGAGCA
TGCACCGGAACCATCTCATCCCTG*C*G*T*G-30 and rw: 50-GGCCGAATTC
GTCGAAACCACTACGCCTCCGC*T*T*T*C-30). PCR reactions were pooled,
puriﬁed with Agencourt AMPureXP DNA beads (Ratio beads/PCR 1.8) and eluted
in 200ml H2O.
Library cloning. The mammalian STARR-Seq screening vector5 has been kindly
provided by Alexander Stark (Vienna, Austria). The screening vector was linearized
by a 6 h digestion with AgeI-HF and SalI-HF (New England Biolabs), followed by
agarose gel electrophoresis, QIAquick gel extraction (Qiagen) and a clean-up with
Qiagen Minelute PCR puriﬁcation Kit (Qiagen). A total of 500 ng of ampliﬁed
captured DNA were recombined (Clontech In-Fusion HD) with 500 ng of the
linearized screening vector (Qiagen) in a total of ten 10-ml reactions (each
containing 50 ng of captured DNA and 50 ng of screening vector). The
recombination reactions were pooled, puriﬁed with Agencourt AMPureXP DNA
beads and eluted in 29ml. Thirteen aliquots (20ml each) of MegaX DH10B
Electrocompetent Bacteria (Life technologies) were transformed with 2 ml of DNA
each, according to the manufacturer’s recommendation. After 1 h recovery at 37 C,
transformations were pooled and transferred to 2 l of LBAMP medium and grown
overnight. Aliquots of the transformation were plated on LBAMP to estimate the
number of cloned fragments. Finally, the plasmid library was extracted using
Qiagen Plasmid Plus Mega Kit (Qiagen).
Library transfection. Transfection of library (5 mg/1 106 cells) was performed
using Neon Transfection System (Life technologies). A total of 30 106 cells were
transfected per experiment. A total of 25 106 cells were used for RNA puriﬁcation
and 5 106 for DNA puriﬁcation. P5424 cells were transfected with 1600v-20ms-1
pulse and 3T3 with 1400v-20ms-2 pulses. Transfected cells were transferred to
complete growth medium and incubated for 24 h before RNA and DNA isolation.
RNA and plasmid isolation from transfected cells. Total RNA was extracted
using RNeasy miniprep kit (Qiagen) with the on-column DNaseI treatment. The
PolyA RNA fraction was isolated using mMACS mRNA isolation kit (Milteny)
following the manufacturer’s instructions. PolyA RNA was treated with Ambion
turboDNase (Ambion) and puriﬁed with RNeasy Minelute kit (Qiagen). Finally,
mRNA was quantiﬁed with Qubit RNA HS Kit (Life technologies). Plasmid DNA
was extracted from 5 106 cells using a QIAGEN plasmid plus mini kit (Qiagen),
following the manufacturer’s instructions.
Reverse transcription and sequencing library preparation. First strand cDNA
synthesis was performed with superscript III (Life technologies) using a reporter-
RNA speciﬁc primer (50-CAAACTCATCAATGTATCTTATCATG-30) and 0.2 to
0.3 mg of polyA RNA per reaction for a total of 10 reactions. After reverse tran-
scription, 1 ml of RNaseH was added (37 C, 1 h). The cDNA was puriﬁed with
QIAquick PCR puriﬁcation kit and concentration was determined with Qubit
ssDNA Kit (Life technologies). The cDNA was ampliﬁed by a 2-step nested PCR
using the KAPA Hiﬁ Hot Start Ready Mix. In the ﬁrst PCR (98 C for 2min;
followed by 15 cycles of 98 C for 20 s, 65 C for 20 s, 72 C for 30 s), 5 ng of cDNA
per reaction was ampliﬁed using two reporter-speciﬁc primers (fw: 50-GGGCCAG
CTGTTGGGGTG*T*C*C*A*C-30 and rw: 50-CTTATCATGTCTGCTCGA*A*G
*C-30), one of which spans the splice junction of the synthetic intron, in a total of
10 reactions. To remove any residual contamination of plasmid or cDNA, PCR
products were puriﬁed on gel using QIAquick gel extraction Kit (Qiagen) followed
by a clean-up with QIAquick minelute PCR puriﬁcation kit (Qiagen). To generate
the Ion Torrent libraries, the puriﬁed PCR was used as a template for the second
PCR (5 ng/PCR, for a total of 10 PCR; 98 C for 2min; followed by 10 cycles of
98 C for 20 s, 65 C for 20 s, 72 C for 30 s) with the KAPA Hiﬁ Hot Start
Ready Mix and Ion Torrent library ampliﬁcation primer mix (Life technologies,
T_PCR_A: 50-CCA TCT CAT CCC TGC GTG TC-30 and P1amp: 50-CCA CTA
CGC CTC CGC TTT CCT CTC TAT G-30). To generate the INPUT control,
10 reactions with 5 ng of reporter constructs (library) per reaction were ampliﬁed
using the same conditions as above, at the exception of the forward primer in the
ﬁrst PCR (fw: 50-GGGCCAGCTGTTGGGGTG*A*G*T*A*C-30). To assess
potential biased in library composition caused by electroporation, 10 reactions with
5 ng per reaction of reporter constructs isolated from transfected cells were
ampliﬁed as described above.
Ion Torrent sequencing. The emulsion PCRs were performed with 25 ml of
Starr-Seq libraries (10 pM) using the Ion PGM Template OT2 400 kit and the
ONE TOUCH 2 system (Life Technologies), according to the manufacturer’s
instructions. Template-positive Ion Sphere Particles were enriched using the Ion
PGM Enrichment Beads (Life Technologies), according to the manufacturer’s
instructions. Finally, libraries were sequenced on ION 318 Chip v2 (Life
Technologies) using the Ion PGM Sequencing 200 kit (Life Technologies),
according to the manufacturer’s instructions.
CapStarr-seq data processing. Sequencing data of CapStarr-seq samples were
mapped to the mouse genome using the Ion PGMTM pipeline (Supplementary
Table 1). Wiggle ﬁles were generated as described in section 4. To quantify the
coverage of each CRM, we intersected the elongated mapped reads (that is, frag-
ments) with the CRMs using BedTools (v2.17.0)31 and calculated FPKM values
(Fragment Per Kilobase per Million mapped reads). After processing the two P5424
biological replicates separately to assess reproducibility (R2¼ 0.90), we pooled both
replicates and re-computed FPKM values for all subsequent analyses. To ﬁlter out
CRMs not captured by the array, all CRMs with a FPKM lower than 1 in the input
sample were excluded, thereby removing 390 CRMs. A total of 7,152 CRMs were
then retained for further analyses (genomic coordinates are provided in
Supplementary Data 1). The enrichment of CapStarr-seq samples over input was
computed by calculating the ratio of FPKM. The FC was used to determine the
enhancer activity of each CRM. CRMs with a FC lower than 1.5 were labelled
‘inactive’, CRMs with a FC between 1.5 and 3 were labelled ‘weak’ and CRMs with
a FC equal or higher than 3 were labelled ‘strong’ (Supplementary Data 1). We
identiﬁed 4,440 inactive, 2,279 weak and 433 strong CRMs in the P5424 pooled
sample, and 4,407 inactive, 2,559 weak and 186 strong CRMs in the 3T3 sample. Of
these 1,205 (33%) weak and 75 (24%) strong CRMs were common to the two cell
types. CapStarr-seq data were visualized using the UCSC genome browser (https://
genome.ucsc.edu/).
FACS analysis. A total of 5 106 P5424 cells were transfected, as described above,
with the empty STARR-Seq screening vector or the STARR-Seq screening vector
containing the library. Twenty-four hours post electroporation, GFP expression
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was assessed on a FACSCalibur (BD Biosciences). For CD4/CD8 staining, 1 106
P5424 cells were incubated for 10min with 5ml of mouse CD4-FITC antibody
(Miltenyi, Ref No 130091608) and with 5 ml of Mouse CD8a-PE (Milteny, Ref No
130102595) in 50mL of PBS/0,5% BSA/2mM EDTA. After washing, CD4 and CD8
expression was analysed on a FACSCalibur (BD Biosciensces).
Gene association. CRM-associated genes were identiﬁed using the online tool
GREAT (Genomic Regions Enrichment of Annotations Tool, v2.0.2)16 with default
settings. GREAT assigns each gene a regulatory domain consisting of a basal region
of  5 kb/þ 1 kb from TSS, and an extension up to the nearest gene’s basal region
but no more than 1Mb in both directions. Each CRM is associated with all genes in
whose regulatory domains it lies. In all, 73.98% of the CRMs were associated with
two genes, 25.94% with only one gene and 0.08% were associated with three genes
(Supplementary Data 1). CRMs were deﬁned as ‘distal’ if they were located at more
than 2 kb upstream and 1 kb downstream the TSS of any annotated gene.
Motif discovery and scanning. The RSAT (Regulatory Sequence Analysis
Tools)32,33 suite was used to perform a de novo motif analysis (peak-motifs tool) in
the different TF ChIP-seq peaks and CRM sets identiﬁed in P5424 cells, as well
as in the whole set of CRMs (Supplementary Fig. 5). We used the matrices for
ETS1/Ikaros, GATA3, HEB, RUNX1 and TCF1 identiﬁed by ChIP-seq to scan the
three sets of CRMs. To assess the quality of the matrices and to determine
thresholds to use for the motif scanning, we used the matrix-quality tool from
RSAT34. We then performed motif scanning in each set of CRMs with adapted
thresholds for each matrix using matrix-scan from the same suite.
Average proﬁles. Average proﬁles were generated by extracting ChIP-seq signal
from wiggle ﬁles around CRMs centre (þ / 5 kb for histone modiﬁcations,
MNase and Pol II; þ / 1 kb for TFs). To test whether the differences between
inactive, weak and strong CRM sets were statistically signiﬁcant, we ﬁrst extracted
the average signal of the top 25% signal of each CRM in a region centred on the
CRM (þ / 1 kb for histone modiﬁcations and MNase; þ / 250 bp for TFs
and Pol II). A Mann–Whitney U-test was then performed between each pair of
CRM sets.
Gene expression. Gene expression data of ab T cells were downloaded from
the Immunological Genome Project website (www.immgen.org). A quantile
normalization was then applied on gene expression of stages ETP (Early Thymic
Progenitor), DN2 (Double Negative stage 2), DN3, DN4, ISP (Immature Single
Positive), DPbl (Double Positive blast), DPsm (Double Positive small) and
single-positive CD4þ (4SP) and CD8þ (8SP) thymocytes. Gene expression in
P5424 cells was analysed in duplicate using the SurePrint G3 Mouse GE 8x60K
microarray platform (Agilent). Statistical signiﬁcance of differences between
inactive, weak and strong CRM sets was calculated using a Student t-test.
Conservation analysis. The genomic evolutionary rate proﬁling (GERP) scores
were used to assess the level of evolutionary constraint of each nucleotide within
and around CRMs. GERP scores, downloaded from the UCSC table browser tool
(mm9 assembly), are based on an alignment of 22 mammals to the Mus musculus
genome (mm9) and have a maximum level of 4.14. The average proﬁle (þ / 1 kb
from the CRM centre) was generated by smoothing GERP scores with a window of
50 bp. Statistical signiﬁcance of differences between inactive, weak and strong CRM
sets was calculated by taking into account the average GERP scores in each CRM
and applying a Mann–Whitney U-test.
Identiﬁcation of super-enhancers. Super-enhancers in DP thymocytes were
identiﬁed using H3K27ac peaks and ROSE tool (http://bitbucket.org/young_
computation/rose)35 with the sequence alignment ﬁles of H3K27ac and Input
samples, the default stitching distance of peaks (12.5 kb) and an exclusion region of
þ / 2.5 kb around TSSs to account for promoter biases. We identiﬁed 1,044
super-enhancers. H3K27ac peaks falling within super-enhancers were called
‘super-enhancer peaks’ and those falling outside super-enhancers were labelled
‘single peaks’. The overlap of H3K27ac peaks with CRMs was performed using
BedTools. The enrichment of CRMs in H3K27ac peaks was calculated using a
hypergeometric test.
Identiﬁcation of highly active loci. We ﬁrst summed up the fold changes of active
CRMs (weak and strong CRMs) associated with each gene. Genes associated with
only inactive CRMs were not included in the analysis. HAL were then determined
by identifying an inﬂection point of the global enhancer activity (sum of fold
changes) versus gene rank. The inﬂection point was computed by determining the
diagonal line of the curve from end points, and by sliding this diagonal line to
ﬁnd where it is tangential. We identiﬁed 375 HAL (Supplementary Data 4).
Enrichments of HAL or remaining loci in gene ontology terms for biological
process were calculated using DAVID tool36 with default settings (count threshold:
2; EASE threshold: 0.1; multiple testing correction by the Benjamini procedure)
and the set of genes associated with CRMs as a background model.
Reporter assay. A total of 1 106 P5424 cells were transiently transfected in six-
well plates with 200 ng of Renilla vector along with 1 mg of pGL3-promoter vector
(Promega) or pGL3-promoter vectors containing the speciﬁed genomic regions
cloned downstream the Luciferase gene (Supplementary Data 3). The transfection
was performed with NEON 100 ml transfection kit (Life technologies) according to
the manufacturer’s protocol. Twenty-four hours after transfection, cells were
washed once with 1 PBS and the luciferase assay (Dual-Luciferase Reporter
Assay System, Promega) was performed according to the manufacturer’s protocols.
Values are expressed as fold increase in luciferase counts over the pGL3-promoter
vector and normalized by the Renilla intensities. All experiments were performed
in triplicates.
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